Back to top
more

Ultragenyx Pharmaceutical (RARE)

(Delayed Data from NSDQ)

$50.36 USD

50.36
1,246,770

-0.07 (-0.14%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.32 -0.04 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of 8.87% and 47.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Up 10.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of 47.44% and 53.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session

by Zacks Equity Research

Ultragenyx (RARE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease

by Zacks Equity Research

Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.

Ultragenyx Gets FDA Nod for Label Expansion of Crysvita

by Zacks Equity Research

Ultragenyx (RARE) gets FDA approval for the label expansion of Crysvita into tumor-induced osteomalacia.

Utragenyx Shares Soar Above 60% YTD on Pipeline Developments

by Zacks Equity Research

Ultragenyx's (RARE) shares rise more than 60% year to date on various positive pipeline developments.

Why Is Ultragenyx (RARE) Up 10.7% Since Last Earnings Report?

by Zacks Equity Research

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -27.50% and -3.70%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Ultragenyx Pharmaceutical Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Ultragenyx Pharmaceutical

Amarin's (AMRN) Q1 Loss In Line With Estimates, Sales Beat

by Zacks Equity Research

Amarin's (AMRN) strong revenue growth in the first quarter is attributable to continued solid demand for its cardiovascular drug, Vascepa.

Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.

Perrigo (PRGO) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.

Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat

by Zacks Equity Research

Alkermes (ALKS) beats earnings and sales estimates for the first quarter of 2020. The company withdraws its previously provided outlook for 2020 amid uncertainty related to coronavirus.

Is a Surprise Coming for Ultragenyx (RARE) This Earnings Season?

by Zacks Equity Research

Ultragenyx (RARE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Down 31.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

Ultragenyx Provides Preliminary Crysvita 2019 Revenues

by Zacks Equity Research

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

Ultragenyx's Gene Therapy Positive in Genetic Disorder Study

by Zacks Equity Research

Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.

Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.